FDA Approval of J&J's Icotyde Sparks 5.2% Drop in AbbVie Shares as Trading Volume Ranks 41st

Market Snapshot

AbbVie (ABBV) shares fell 5.20% on March 18, 2026, closing at approximately $212.50. The stock opened below the previous day’s close of $218.60 and traded within a range of $209.42 to $218.60. Trading volume surged by 85.52% to $1.80 billion, ranking 41st in market activity for the day. The decline followed the U.S. Food and Drug Administration’s (FDA) approval of Johnson & Johnson’s (J&J) Icotyde, a once-daily oral plaque psoriasis treatment that directly competes with AbbVie’s flagship drug, Skyrizi.

Key Drivers

The FDA’s clearance of Icotyde, co-developed with Protagonist Therapeutics (PTGX), triggered immediate market concerns over Skyrizi’s dominance in AbbVie’s immunology portfolio. Icotyde’s oral formulation and convenient dosing schedule position it as a direct rival to Skyrizi, which has been a critical revenue driver for AbbVie in the post-Humira era. Analysts noted that the approval introduces near-term competition for Skyrizi, which had been expected to grow by 23% in fiscal year 2026. Despite this, Wall Street maintains optimism about Skyrizi’s long-term prospects, citing its proven efficacy and dosing advantages.

Technical indicators further underscored bearish sentiment. ABBV closed below its 20-day ($227.73), 50-day ($224.27), and 200-day ($214.95) moving averages, signaling sustained selling pressure. The Relative Strength Index (RSI) and Commodity Channel Index (CCI) indicated oversold conditions, while the Average Directional Index (ADX) suggested a lack of clear trend formation. Key support levels were identified at $210.83, with a breakdown below this threshold potentially accelerating the decline.

AbbVie’s broader challenges compound the near-term risks. The company continues to grapple with the revenue impact of Humira’s patent expiration and ongoing sales declines in its aesthetics division. Institutional investors have reduced holdings in ABBV, reflecting shifting sentiment, while corporate insiders have executed two selling transactions in the past three months. However, AbbVie’s strategic partnership with Alloy Therapeutics to advance antibody discovery and its FY2026 earnings per share (EPS) guidance of $14.37–$14.57 signal efforts to stabilize its growth trajectory.

The competitive landscape for Skyrizi remains fluid. While Icotyde’s approval threatens to capture market share, analysts emphasize that Skyrizi’s clinical differentiation—particularly its administration schedule and efficacy—may limit its immediate impact. Additionally, AbbVie’s collaboration with Alloy Therapeutics provides a pipeline boost, potentially offsetting some revenue pressures. The stock’s GF Value estimate of $198.80 suggests it trades near fair valuation, though technical indicators and competitive dynamics continue to favor sellers in the short term.

Market Outlook and Strategic Implications

The approval of Icotyde highlights the intensifying competition in the psoriasis market, where AbbVie’s Skyrizi faces challenges from both established players and emerging therapies. While Wall Street’s consensus price target of $251.44 remains in place, the 5.20% drop underscores investor caution. AbbVie’s ability to maintain Skyrizi’s market share will depend on its capacity to differentiate through clinical outcomes and patient adherence. Meanwhile, the company’s focus on R&D partnerships and diversified revenue streams—such as its aesthetics division and oncology assets—will be critical in mitigating near-term headwinds.

In the technical realm, traders are monitoring a potential consolidation between $210.83 and $215.22, with a rebound expected if the stock consolidates near the lower boundary. However, the SMA-200 at $214.95 offers limited support, and the overall technical setup remains bearish. Institutional ownership at 74.71% indicates sustained confidence, but evolving competitive dynamics and macroeconomic factors, such as healthcare sector volatility, could further influence ABBV’s trajectory in the coming quarters.